PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis on Bell2Bell Podcast

On the latest episode of The Bell2Bell podcast, PaxMedica CEO Howard Weisman and Dr. Marshal Lemerani, Program Manager at the Malawi Ministry of Health, join host Stuart Smith.

PaxMedica Answers Malawi Ministry of Health's Urgent Need for Suramin

Dr. Marshal Lemerani, Program Manager for Trypanosomiasis (African Sleeping Sickness) for the Malawi Ministry of Health, examines a recently produced vial of PaxMedica’s PAX-101 (IV Suramin).

PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell Podcast

David Hough shared key updates following PaxMedica's recent meeting with the FDA, highlighting pivotal achievements

PaxMedica Announces Publication of Its Autism Spectrum Disorder Phase 2 Study Results in Peer-reviewed Journal

Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder

PaxMedica, Inc. (Nasdaq: PXMD) featured Bell2Bell Podcast

Explore the comprehensive interview on the Bell2Bell Podcast, where PaxMedica, Inc., a prominent clinical-stage biopharmaceutical firm.

H.C. Wainwright 25th Annual Global Investment Conference

Live on Tuesday, 9/12 at 3:00 PM (Eastern Standard Time)

PXMD Business Update

Business Briefing: SIGNIFICANT PHASE 3 PAX-HAT-301 STUDY RESULTS; PROGRESSING TOWARD START OF MULTI-CENTEREDCLINICAL TRIALS IN ASD

Positive Top Line Results

PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301

PaxMedica Grants Exclusive Pharmacy Distribution Rights

Exclusive pharmacy distribution agreement for PaxMedica’s lead pipeline asset, PAX-101, granted to Vox Nova LLC

The BRAIN Foundation Presents: Suramin for Autism

PaxMedica CEO Interviewed by The BRAIN Foundation

PaxMedica Rings the NASDAQ Closing Bell

PaxMedica Celebrates Autism Awareness Month

Discussing Priority Review Vouchers With Chief Medical Officer Stefan Schwabe

Discussing Priority Review Vouchers With Chief Medical Officer Stefan Schwabe

Paxmedica Diving into the Investor Presentation with CEO Howard Weisman

PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders.

PaxMedica Holds Meeting of Scientific Advisory Board

Board Includes Several Key Opinion Leaders on Autism Spectrum Disorder in U.S.

PaxMedica Plans to Initiate Phase 1B Study for PAX-101 in Patients with Long COVID-19 Syndrome

Study has been approved by the South African Health Authority for individuals with documented COVID-19 infections who develop debilitating physical and neuropsychiatric symptoms that persist for...

PaxMedica selected by American Academy of Child and Adolescent Psychiatry (AACAP) to Present Data from its Recent Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD) in the Research Pipeline Program

David Hough, MD, CMO of PaxMedica will present trial results at the upcoming AACAP Annual Meeting during the “Research Pipeline: New Findings on Diagnostics and Therapeutics” program...

PaxMedica Announces Positive Results from Phase 2 Trial of PAX-101 (IV suramin) in Children with Autism Spectrum Disorder (ASD)

PAX-101 demonstrated sustained improvements over placebo in the trial’s primary and several secondary endpoints and a favorable safety and tolerability profile

PaxMedica Receives FDA Orphan Drug Designation for Use of PAX-101 (IV suramin) in a Rare Tropical Disease

Company Pursuing Development of PAX-101 as Treatment for Autism Spectrum Disorder and Other Neurodevelopmental Conditions